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The human T-lymphotropic virus type-1 (HTLV-1) is etiologically linked to adult T cell
leukemia/lymphoma and tropical spastic paraparesis/HTLV-1-associated myelopathy.While
the role of Tax and Rex in viral replication and pathogenesis has been extensively studied,
recent evidence suggests that additional viral proteins are essential for the virus life cycle
in vivo. In this review, we will summarize possible molecular mechanisms evoked in the lit-
erature to explain how p12, p8, p30, and p13 facilitate persistent viral infection of the host.
We will explore several stratagems used by HTLV-1 accessory genes to escape immune
surveillance, to establish latency, and to deregulate cell cycle and apoptosis to participate
in virus-mediated cellular transformation.
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INTRODUCTION
Expression of viral proteins and replication is under the control of
virus long terminal repeat (LTR) transactivator Tax and viral RNA
export Rex proteins (Kashanchi and Brady, 2005). The regula-
tion of human T-lymphotropic virus type-1 (HTLV-1) structural
protein(s) expression and their processing has been previously
reviewed (Le Blanc et al., 2001; Fogarty et al., 2011). Unlike animal
oncoretroviruses the HTLV-1 proviral genome encodes a unique
pX region, which, through alternative splicing and different trans-
lation initiation sites, generates seven viral regulatory proteins
(Ciminale et al., 1992; Koralnik et al., 1993). This complexity is
remarkable and highlights the high level of adaptation the virus
employs in making the most out of its relatively small genome.
All regulatory proteins are expressed in HTLV-1 cell lines and in
patients infectedwithHTLV-1 (Pique et al., 2000; Satou et al., 2006;
Saito et al., 2009). Expression of these proteins is absolutely essen-
tial for virus replication in an in vivo non-human primate model
for HTLV-1 (Valeri et al., 2010).
Open reading frame-I (ORF-I) encodes the p12 protein, a
small hydrophobic protein which can be further processed into
p8 (Koralnik et al., 1993). p12 and p8 have different cellular local-
izations and distinct functions (Van Prooyen et al., 2010a). Recent
studies indicate that some of the functions once attributed to p12
actually belong to p8. ORF-II produces the p30 and p13 proteins.
Althoughp13 encodes the carboxyl terminal 87 amino acids of p30,
their cellular localizations and functions are signiﬁcantly differ-
ent (Koralnik et al., 1993; Baydoun et al., 2008; Silic-Benussi et al.,
2010a). Rex and Tax, corresponding to ORF-III and ORF-IV, are
encoded by the same doubly spliced RNA (Kashanchi and Brady,
2005). HBZ is encoded from a complementary minus-stranded
RNA transcript from the 3′-LTR (Gaudray et al., 2002; Murata
et al., 2006). In addition, the pX region also produces two other
proteins, p21-Rex and Rof (p12 Rex Orf I). This review will focus
on the role of HTLV-1 regulatory genes in virus infection, immune
escape, and transformation.
ROLE OF HTLV-1 REGULATORY GENES IN VIRUS INFECTION
AND VIRAL SPREADING IN VIVO
In contrast to Tax and Rex, HTLV-1 regulatory genes p12, p8,
p30, and p13 are not absolutely required for virus replication and
for the immortalization of human primary T cells in vitro (Derse
et al., 1997; Robek et al., 1998; Lairmore et al., 2000). However,
several studies have found that human T cell lines immortal-
ized with HTLV-1 molecular clones lacking p12 or p30 grow less
efﬁciently than their wild-type counterpart clones and are more
dependent upon the presence of interleukin-2 (IL-2) in the media
(Albrecht et al., 2000; Nicot et al., 2001; Taylor et al., 2009a). Inves-
tigations using a rabbit model to study HTLV-1 infection in vivo
suggested that p12, p30, and p13 may all be required for viral
infectivity (Bartoe et al., 2000; Silverman et al., 2004; Hiraragi
et al., 2006). However, the subsequent discovery of a new viral
gene, HBZ, encoded from an overlapping complementary minus-
stranded RNA transcript from the 3′-LTR, challenged conclusions
made in these studies. Mutations aimed at knocking out p12, p30,
and p13 in HTLV-1 molecular clones all affected the HBZ cod-
ing sequence, a gene necessary for virus infectivity (Matsuoka
and Jeang, 2007; Yasunaga and Matsuoka, 2011). Recently, the
role of HTLV-1 regulatory genes was re-investigated using new
HTLV-1 molecular clones carrying a single viral gene knock-out,
whereby HBZ expression was not affected. These studies, which
were performed both in rabbits and in non-human primates,
clearly demonstrated that only non-human primates constitute
an appropriate in vivomodel for HTLV-1 infection and replication
(Valeri et al., 2010).
HBZ,p12, and p30were found to be essential forHTLV-1 infec-
tion and replication in non-human primates but p12 and p30were
dispensable in rabbits (Valeri et al., 2010). Interestingly, it appears
that the requirement of p12 and p30 for infectivity in vivo is related
to their ability to sustain HTLV-1 replication in dendritic cells
(DCs) in in vitro and in vivo infection of macaques (Valeri et al.,
2010). These results also conﬁrmed earlier studies showing that
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HTLV-1 infection of DCs is essential for initial viral spread (Jones
et al., 2008). These observations are very critical in understand-
ing the development of adult T cell leukemia/lymphoma (ATLL),
because HTLV-1 must spread rapidly to its target cells to establish
a latent infection and avoid clearance by the immune system.
HumanT-lymphotropic virus type-1 cell free virions are poorly
infectious and require cell-to-cell transmission. In this regard it is
interesting to point out studies that have demonstrated a role for
p12 in facilitating cell-to-cell viral spread by inducing lymphocyte
function-associated antigen-1 (LFA-1) clustering on T cells. These
effects relied upon calcium-dependent signaling and increased
nuclear factor of activated T cells (NFAT)-dependent transcrip-
tion (Kim et al., 2006). Therefore, p12 may play an essential role
in the very early stages of HTLV-1 infection.
TRANSCRIPTIONAL REGULATION OF VIRAL EXPRESSION BY
REGULATORY GENES
Once the HTLV-1 virus establishes infection it is critical for the
virus to repress viral gene expression in order to reduce viral anti-
gens and avoid being recognized by the immune system. Tax and
Rex are potent positive regulators of viral expression andTax is also
the main target of cytotoxic T lymphocytes (CTLs; Koenig et al.,
1993). Because of this, the HTLV-1 virus employs different ways
to interfere with Tax function and to reduce Tax expression. p30,
p13, and p8 all negatively regulate viral expression (Figure 1; Nicot
et al., 2004; Andresen et al., 2011). Tax activates the transcription
of viral genes through the recruitment of cAMP response element-
binding protein (CREB) and cellular coactivators CREB-binding
protein (CBP), p300 and p300/CBP-associated factor (PCAF) to
the Tax-response elements (TRE) within the U3 region of the LTR
(Kashanchi and Brady, 2005). Some studies have demonstrated
that p30 has the ability to attenuate the formation of active tran-
scriptional complexes on the TRE and can interact with CBP/p300
via the KIX domain (Zhang et al., 2001). Because Tax recruits
CBP/p300 via the same domain, Tax and p30 are proposed to
compete with each other for CBP/p300 binding. However, these
observations were made in an over-expression experimental sys-
tem and are therefore subject to discrepancy (Nicot et al., 2004).
In another study, whereby p30 was expressed from an HTLV-1
molecular clone, p30 could not decrease virus production (Valeri
et al., 2010). This is expected when the expression level of Tax and
p30 are taken into account, as there is much more Tax than p30
mRNA and proteins in HTLV-1 transformed cells in vitro than
in transiently transfected cells, which may not accurately reﬂect
the expression levels of these proteins in vivo. The relative level
of these proteins in ATLL cells in still unknown and may also
vary in distinct cellular sub-populations. A recent study showed
the expression level of p30 was about 1/1000 of tax/rex RNA in
ATLL samples after in vitro culturing for 2 h (Rende et al., 2011).
However, this ratio might not reﬂect the actual ratio in vivo.
In addition to viral gene transcription, genome-wide analysis
revealed that p30 modulates the transcription of numerous cellu-
lar genes. Sixty-ﬁve genes were found to be down-regulated greater
than 2.5-fold in the presence of p30. These genes were found to be
associated with cell signaling, transcription/translation, cell cycle,
and metabolism (Taylor et al., 2009b). In contrast to repressed
genes, only 15 cellular genes were up-regulated and mostly
corresponded to genes involved in transcription/translation and
RNA processing (Taylor et al., 2009b).
A recent study showed that p13 is also able to inter-
fere with Tax transactivation. Using GST pull-down and co-
immunoprecipitation assays, p13 was shown to interact with Tax,
and its presence can decrease Tax’s interaction with p300. Inter-
estingly, the fact that an increasing amount of p300 can partially
rescue the repression by p13 on the HTLV-1 LTR reporter also
indicates a competition mechanism. In fact, p13 and CBP/p300
have been shown to compete for Tax interaction. Notably, even
when p13 was expressed naturally from an HTLV-1 molecular
clone, it can still repress viral replication. The difference between
p13 and p30 mediation of Tax transactivation might be caused
by two factors. Firstly, a previous study showed that in transient
transfection with an HTLV-1molecular clone, there was more p13
expression than p30 expression. Secondly, the stability of p13 can
be greatly increased by Tax. In addition to p30 and p13, stud-
ies show that a p12-processed p8 protein can also decrease viral
transcription through mediation of T cell receptor (TCR) sig-
naling. Previous studies demonstrate that activation of the TCR
increases viral replication. The TCR complex consists of a vari-
able ligand-binding TCRαβ heterodimer and a non-variable signal
transduction CD3 complex including CD3γ, CD3δ, CD3ε, and a
TCRζ subunit. TCR signaling occurs through a cascade of events.
It is not clear how the TCR pathway activates viral transcrip-
tion, but some evidence suggests that lymphocyte-speciﬁc protein
tyrosine kinase (Lck) plays a signiﬁcant role in transduction. Stud-
ies have demonstrated that p8 inhibits TCR signal transduction
and reduces viral expression. When the non-canonical endoplas-
mic reticulum (ER) retention/retrieval signal (1–9 aa) within the
amino terminus is removed from p12, the protein was trans-
ported to the Golgi apparatus, where another cleavage between
amino acids 29 and 30 produced p8 and stimulated its expres-
sion at the cell surface. When the TCR is activated and forms the
immunologic synapse (IS), p8 is quickly recruited to the IS. In
the IS, p8 binds to the linker of activated T cells (LAT) protein
and inhibits its activity, as evidenced by the decreased phosphory-
lation of phospholipase C-gamma1 (PLC-γ1) and Vav. A similar
inhibition was observed when p8 was expressed from an HTLV-1
molecular clone.
POST-TRANSCRIPTIONAL REGULATION OF VIRAL
EXPRESSION BY REGULATORY GENES
In addition to transcription, prior studies show that p30 can neg-
atively regulate viral expression after transcription. We found that
p30binds to a response elementwithin the tax/rexRNAand retains
the viral RNA in the nucleus. This further reduces Tax expres-
sion and silences virus expression (Nicot et al., 2004, 2005). When
over-expressed, p30 efﬁciently represses viral replication in both
transient transfection assays and HTLV-1-infected cells, such as
MT2 and C91PL (Nicot et al., 2004). Interestingly, recent stud-
ies demonstrated that ablation of p30 from an HTLV-1 molecular
clone reduced replication; and HBZ suppressed HTLV-1 replica-
tion by targeting p30 mRNA (Choudhary and Ratner, 2011).
We recently found that p30 interacts with PA28gamma (PA28γ)
and recruits it to the tax/rex RNA. The binding of PA28γ to tax/rex
RNA is p30-dependent. In 293FT cells knocked-down for PA28γ
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FIGURE 1 | Schematic functional representation of p12, p8, p30 and p13 in HTLV-1 infection.
expression, viral production from transfected HTLV-1 molecular
clones signiﬁcantly increased. In an HTLV-1 positive ATLL cell
line, the knock-down of PA28γ increased tax/rex RNA and Tax
proteins. These studies support the notion that endogenous p30
expressed under physiological conditions from the provirus can
regulate tax/rex expression.
ROLE OF HTLV-1 SMALL REGULATORY GENES IN HOST
IMMUNE ESCAPE AND IMMUNOSUPPRESSION
There is abundant evidence that HTLV-1-speciﬁc CTLs are efﬁ-
cient against HTLV-1-infected cells and play a signiﬁcant role in
determining the proviral load (Bangham, 2000; Bangham and
Osame, 2005; Akimoto et al., 2007; Bangham et al., 2009). So far,
there is evidence that most of the viral proteins can be targeted by
CTLs. However, it is generally accepted that the dominant target of
CTLs is the Tax protein. In addition, natural killer (NK) cells can
also kill HTLV-1-infected cells. Despite this, HTLV-1 is still able
to establish persistent infection in its host. Studies show that the
virus employs different strategies to remain silent. First, it represses
viral gene expression, while persisting in the host through prolifer-
ation of infected cells (Saggioro et al., 1991; Newbound et al., 2000;
Rahman et al., 2012). Second, the virus has also evolved ways to
interfere with the immune response of the host.
p8 STIMULATES FORMATION OF VIRAL TUNNELS FOR INFECTION OF
NEIGHBORING CELLS
Although there is evidence that cell-free HTLV-1 virus can infect
DCs, it is generally accepted that HTLV-1 is mainly transmitted
through cell-to-cell contacts, such as virological synapses and cel-
lular conduits (Nejmeddine et al., 2005). Studies show that p8
increases virus transmission between cells through cellular con-
duits. Studies showed that p8 enhances cell adhesion by inducing
LFA-1 clustering without changing LFA-1’s expression or afﬁnity
(Van Prooyen et al., 2010b). Immunoﬂuorescence demonstrated
that p8 co-localizedwith the clustered LFA-1. It was further proved
that p8 expressed from the HTLV-1 molecular clone had the same
effects (Van Prooyen et al., 2010b). The HTLV-1 virus trafﬁcs
through the conduits, as evidenced by the presence of mature
viral particles at the contact site between two conduits or between
a conduit and the surface of the target T cell. Collectively, p8 pro-
vides the virus with a new way to infect cells hiding from immune
defenses (Van Prooyen et al., 2010b).
DOWN-MODULATION OF MHC-1 BY p12
Cytotoxic T lymphocytes target HTLV-1-infected cells through
the TCR, which recognizes the viral peptide presented by the
major histocompatibility complex class I (MHC-1). The MHC-
1 consists of a heavy chain (Hc) containing the peptide binding
site and β2-microglobulin, which are assembled in the lumen of
the ER. Viral peptides, generated by the proteasome, are trans-
ported into the ER, where the three components assemble in
ternary complexes and are transported to the cell surface. The
abnormality of the assembly and trafﬁcking of MHC-1 helps the
infected cells to evade recognition by theCTL, contributing to viral
persistence. Studies show that p12 interferes with the assembly and
decreases from the cell surface MHC-1. p12 speciﬁcally binds to
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newly synthesized, less glycosylated MHC-1-Hc before it forms a
heterodimer with β2-microglobulin (Johnson et al., 2001; John-
son and Franchini, 2002). Three different humanMHC-1-Hc-A2,
B7, and Cw4 complexes were tested and all of them interacted
with p12. Upon binding, the MHC-1-Hc and p12 complex is
rerouted to the cytosol and degraded by the proteasome. Cellular
immunoﬂuorescence demonstrated that p12 also interfered with
the trafﬁcking of MHC-1 and, consequently, the level of MHC-1
on the cell surface decreased. In addition, in the presence of p12, a
decrease of endogenous MHC-1 was also demonstrated (Johnson
et al., 2001). Moreover, theMHC-1molecules were decreased after
primary CD4+ T cells were infected by theHTLV-1 virus (Johnson
et al., 2001).
REDUCTION OF ICAM-1 AND ICAM-2 BY p12
As stated above, the HTLV-1 virus down-regulates cell surface
MHC-1 to evade CTLs. At the same time, the down-regulation of
MHC-1 may expose the infected cells to NK cells. It is also known
that Tax increases IL-2 expression (Ballard et al., 1988; Ruben et al.,
1988), which promotes NK cell proliferation and enhances LFA-1-
mediated adhesion of NK cells to intercellular adhesion molecules
(ICAMs) on target cells. Taken together, this suggests that NK
cells can easily adhere to and kill HTLV-1-infected cells (Stewart
et al., 1996). Surprisingly, studies show there was little difference
between NK cell cytotoxicity of the mock-infected cells and the
HTLV-1-infected cells. Also, pretreatment of cells with IL-2 just
marginally increasedNKcell cytotoxicity toHTLV-1-infected cells.
Further studies demonstrated that HTLV-1 infection speciﬁcally
decreased the expression of ICAM-1 and ICAM-2, but not ICAM-
3 on primary T cells (Banerjee et al., 2007). Moreover, it was
demonstrated that expression of p12 alone is sufﬁcient to down-
modulate them (Banerjee et al., 2007). In addition, lack of natural
cytotoxicity receptor (NCR) and NKG2D ligand expression from
HTLV-1-infected cells might also affect NK cell activity. So far,
it is not clear whether p12 or p8 mediate the down-modulation
of ICAM-1 and ICAM-2, and the mechanism for doing so also
remains to be seen.
INHIBITION OF TLR-4 SIGNALING BY p30
IN MACROPHAGES
Although the primary target of HTLV-1 is CD4+ cells, many other
kinds of cells can also be infected both in vivo and in vitro, such
as monocytes, macrophages, and DCs (Jain et al., 2009). These
cells are important for innate immunity and play a major role in
antigen presentation. There are some reports stating that infec-
tion by HTLV-1 interferes with the differentiation and function of
DCs. Our studies show that p30 interferes with Toll-like receptor-
4 (TLR-4) signaling in human macrophages (Datta et al., 2006;
Bai et al., 2010). TLR-4 is the major lipopolysaccharide (LPS)
receptor and elicits an innate immune response against Gram-
negative bacteria. We found that p30 binds to and inhibits PU.1
DNA binding and that p30 inhibits endogenous PU.1-mediated
transcription from a PU.1 reporter in humanmacrophages (Datta
et al., 2006). In addition, p30 reduces endogenousPU.1 expression.
The inhibition of PU.1 by p30 was further evidenced by a decrease
in TLR4 expression (Datta et al., 2006). Notably, when p30 was
expressed fromanHTLV-1molecular clone, it still down-regulated
TLR-4 expression. Consistent with this, in the presence of p30,
the release of pro-inﬂammatory cytokines monocyte chemotactic
protein-1(MCP-1), tumor necrosis factor-alpha (TNF-α), and
IL-8 decreased after stimulation with LPS (Datta et al., 2006).
Although innate and adaptive immune responses have been
thought to be non-overlapping, recent evidence clearly indicates
that the interplay between components of the immune system
occurs frequently and forms the basis of effective immunity. The
impact of inhibition of PU.1 by p30 on the host immune response
remains to be studied.
Recent studies highlight another side of macrophage and DC
infection. They are not just “victims” of the HTLV-1 virus, but
may actually help virus transmission, dissemination and persis-
tence (Jones et al., 2008). The importance of these observations
remains to be clariﬁed. Interestingly, an HTLV-1 molecular clone
with p12 or p30 ablation cannot infect human primary DCs,
suggesting that they play an essential role in DC infection (Valeri
et al., 2010).
HOW HTLV-1 REGULATORY GENES STIMULATE T CELL
PROLIFERATION, AFFECT DNA REPAIR, AND PROMOTE
CELLULAR TRANSFORMATION
ACTIVATION OF STAT5b BY p12
Interleukin-2 is an important cytokine that drives T cell prolif-
eration. There are three different IL-2 receptors (IL-2R): α chain
(IL-2Rα), β chain (IL-2Rβ), and γ chain [IL-2Rγ, also known
as the common cytokine receptor γ chain (γc)]. Ligand-speciﬁc
IL-Rα (CD25) is expressed on activated lymphocytes and binds
IL-2 with low afﬁnity. The IL-2Rβ/IL-2Rγ complex binds IL-2
with intermediate afﬁnity. When all three receptors are expressed
on activated T cells, IL-2 is bound with high afﬁnity. The inter-
mediate and high afﬁnity receptor forms are responsible for IL-2
signal transduction (Waldmann et al., 1998; Imada and Leonard,
2000). Binding of IL-2 leads to the heterodimerization of the
cytoplasmic domain of IL-2Rβ and γc , followed by the recruit-
ment of Janus kinase 1 (Jak1) and Jak3. Then, Jak1 and Jak3
activate signal transducers and activators of transcription (STAT)
proteins through phosphorylation. IL-2Rβ is essential for STAT
protein docking and activation (Waldmann et al., 1998; Imada
and Leonard, 2000). In HTLV-1 cells, there exists constitutive
activation of the Jak/STAT pathway (Migone et al., 1995, 1998;
Xu et al., 1995; Takemoto et al., 1997). Although Tax can acti-
vate the Jak/STAT pathway through inducing IL-2, IL-2Rα, and
STAT5 expression, the fact that there is little or no Tax expres-
sion in the majority of ATLL patient samples indicates that
another mechanism exists. p12 has the ability to activate the
Jak/STAT pathway. p12 signiﬁcantly increased the transcriptional
activity and DNA binding of STAT5b (Nicot et al., 2001). The
activation required the presence IL-2Rβ, γc , and Jak3. Forced
expression of p12 in peripheral bloodmononuclear cells (PBMCs)
also resulted in more STAT5 phosphorylation and DNA bind-
ing. Consistent with the activation of the Jak/STAT pathway by
p12, t p12 decreases the IL-2 requirement for T cell prolifera-
tion and promotes cell proliferation by limiting the concentration
of IL-2 (Nicot et al., 2001). In addition, p12 also increases the
colony formation potential of HTLV-1 with and without IL-2. It
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is notable that when p12 was expressed naturally in the HTLV-1
molecular clone, it still decreased the cells’ dependency on IL-2
(Nicot et al., 2001).
p12 DEREGULATES Ca2+ AND NFAT
Except for the Jak/STAT pathway, p12 also has the ability to acti-
vate another important T cell transcription factor, the NFAT.
There are ﬁve members in the NFAT family. Among them, NFAT1
to NFAT4 are regulated by intracellular Ca2+ signaling and, in
activated T cells, NFAT2 is the predominantly induced factor.
Puriﬁed NFAT is heavily phosphorylated and is dephosphorylated
by the phosphatase calcineurin. All kinds of stimuli that activate
NFAT will ﬁrst result in the release of Ca2+ from the ER. The
released Ca2+ in the cytoplasm activates the Ca2+ sensor calmod-
ulin, followed by the activation of the calmodulin-dependent
phosphatase, calcineurin (Medyouf and Ghysdael, 2008; Oh-
hora and Rao, 2009). Calcineurin dephosphorylates multiple
phosphoserines from the regulatory domain of NFAT and acti-
vates NFAT. The activated NFAT translocates into the nucleus
and cooperates with transcriptional factors, including activator
protein-1 (AP-1), to activate transcription. p12’s ability to acti-
vate NFAT is related to its ability to increase cytoplasmic Ca2+
(Albrecht et al., 2002; Ding et al., 2002; Kim et al., 2003). In
support of this conclusion, activation can be blocked by BAPTA-
AM [glycine, N,N ′-1,2-ethanediylbis(oxy-2,1-phenylene)-bis-N-
2-(acetyloxy) methoxy-2-oxoethyl]-[bis(acetyloxy)methyl ester],
a sequester of intracellular calcium. How p12 increases cellular
calcium is not clear. However, that 2-APB, an inositol
1,4,5-trisphosphate (IP3) receptor, and SKF 96365, a chemical
inhibitor of release-activated calcium (CRAC) channels in the
plasma membrane, can partially block the activation implies
that both ER calcium releasing and extracellular-calcium inﬂux
contribute to the cytoplasmic calcium increase. In addition,
cyclosporinA and a dominant negative NFAT2mutant also inhibit
the activation by p12. It is also reported that p12 has a cal-
cineurin binding motif PSLP(I/L)T, which is highly homologous
to the PXIXIT calcineurin binding motif of NFAT. p12 binds
to calcineurin and competes with NFAT for calcineurin bind-
ing (Albrecht et al., 2002; Ding et al., 2002; Kim et al., 2003).
Because both activated STAT5 and NFAT can bind to the IL-2
promoter and increase transcription, the presence of p12 should
enhance IL-2 production. As expected, p12 expression in Jurkat
T cells and PBMCs enhances IL-2 production. The enhanced
IL-2 production by p12 was calcium-dependent, which sug-
gests that the NFAT pathway might be even more important
to p12 in enhancing IL-2 production. In addition, the quanti-
ties of IL-2 elicited from p12-expressing PBMCs were sufﬁcient
to promote PBMC proliferation. Interestingly, we found that
IL-2 increased HTLV-1 virus transmission. We further demon-
strated that inhibition of Jak/STAT signaling decreased virus
transmission. Transmission was associated with promotion of cell
membrane fusion, but not with virus production, cell–cell adher-
ence, gags polarization, or virological synapse formation. This
mechanism remains to be clariﬁed. Except for all the advantages
of IL-2, it also stimulates CTL proliferation and evokes NK cell
cytotoxicity toward HTLV-1-infected cells, helping to eradicate
them.
p30 ALTERS CELL CYCLE AND DNA REPAIR TO PROMOTE
TRANSFORMATION
Using microarray analysis, the effect of p30 on gene expres-
sion was studied by two different groups (Datta et al., 2007;
Taylor et al., 2009b). Based on the changes in gene expression,
p30 modulates many aspects of cell function, such as apop-
tosis, cell cycle, T cell activation and signal transduction, and
transcription/translation/RNA processing factors. Overall, p30
down-regulates more genes than it up-regulates. We also stud-
ied the effect of p30 on RNA export and found that p30 increased
or decreased a large portion of genes in the cytoplasm. The bio-
logical signiﬁcance of these changes remains to be tested. It is
of note that all these assays were based on over-expression sys-
tems. Based on the array data, p30 was tested on NF-κβ, AP-1,
and NFAT reporters with and without co-stimulators of T cells,
including phorbol 12-myristate 13-acetate (PMA), ionomycin,
anti-CD3, and anti-CD28. p30 activated all three reporters in
Jurkat T cells (Datta et al., 2007). Collectively, these data sug-
gested that p30, like p12, has the potential to promote T cell
proliferation. However, the role of p30 in regulating the cell
cycle of T cells is not yet determined, and so far three studies
have had different results. In one study, it was demonstrated that
p30 results in a delay in the G2 phase of the cell cycle (Datta
et al., 2007). In addition, the p30 transduced Jurkat T cells pro-
liferated slowly compared to the mock-infected cells. The delay
was associated with the G2-M transition checkpoint, including
phosphorylation of checkpoint kinase-1 (Chk1) at serine 345,
phosphorylation of Cdc25C at serine 216, reduced amounts of
Polo-like kinase-1 (PLK1) and the threonine 210 phosphory-
lated form of PLK1 and dephosphorylation of Cdc2 at threonine
198 and 216 (Datta et al., 2007). However, in another study it
was found that p30 inhibits G1-S progression and retains cells
in G1 in both HeLa and Jurkat T cells (Baydoun et al., 2010).
p30 prevents S phase entry by targeting multiple checkpoints,
as evidenced by reduced phosphorylation of retinoblastoma pro-
tein (Rb), decreased expression of E2F, proliferation cell nuclear
antigen (PCNA), and Cyclin E, and increased expression of
p21 waf (Baydoun et al., 2010). In addition, we demonstrated
that p30 interacts with both CDK2 and Cyclin E and reduces
active CDK2–Cyclin E complex formation (Baydoun et al., 2010).
Because Tax promotes cell cycle progression, especially at the
G1-S phase transition (Franchini et al., 2003), p30 has a new
way to negatively regulate Tax. Further studies are needed to
understand the function of p30 on cell cycle and the relation-
ship(s) between deregulation of the cell cycle, viral persistence,
and leukemogenesis.
In addition to deregulation of the cell cycle, p30 also inter-
feres with DNA repair to promote cancer. In a recent study, it
was found that p30 inhibits homologous recombination (HR)
repair (Baydoun et al., 2011). When there was a DNA double
strand break (DSB) caused by drugs or irradiation, p30 re-
localized from the nucleoli to the nucleoplasm. p30 re-localization
was associated with phosphorylation of p30 at threonine 232
by the mitogen-activated protein kinase (MAPK) signaling path-
way, since re-location was blocked by a threonine to alanine
mutation at 232 of p30 and the MAPK inhibitor, PD98059
(Baydoun et al., 2011). Several pieces of evidence indicated that
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amino acids 221–254 of p30’s c-terminus are not involved in
HR. Notably, p30 was demonstrated to interact with both nibrin
(NBS1) and RAD50, but not MRE11, and p30 was able to reduce
the assembly of functional Mre11–Rad50–NBS1 (MRN) com-
plexes onto DSBs (Baydoun et al., 2011). Moreover, p30 also
disrupted the MRN complex formation on naturally occurring
DSBs during S-phase. Corresponding to a decrease in HR repair
was an increase in error-prone non-homologous end-joining
(NHEJ) repair. Collectively, these data suggest that p30 increases
the instability of the genome and plays an important role in T
cell transformation and leukemogenesis (Baydoun et al., 2011).
Our ﬁnding is consistent with the facts that p30 protects cells
from camptothecin, a topoisomerase I inhibitor, which induces
apoptosis in cells in the S phase of the cell cycle, and irra-
diation. A recent study also showed that p30 binds to ataxia
telangiectasia mutated (ATM) and modulates its phosphoryla-
tion to prevent apoptosis (Anupam et al., 2011). In addition to
increasing genomic instability, p30 also promotes transformation
through enhancing the transcriptional and transforming activity
of Myc. p30 interacts with both Myc and TIP60 and helps Myc to
recruit more TIP60 to the Myc transcriptional complex (Awasthi
et al., 2005).
THE ROLE OF p13 IN PRO-APOPTOSIS AND INHIBITION OF TUMOR CELL
PROLIFERATION
p13 localizes to both nuclear speckles and mitochondria depend-
ing on the cellular context and expression level (D’Agostino
et al., 2000). The amino acids 21–30 of p13, the minimal mito-
chondrial targeting sequence, are responsible for mitochondria
targeting. Studies show that p13 might form an amphipathic
α- helix across the inner membrane and trigger an inward K+
and Ca+ current that causes depolarization, activation of the
electron transport chain and augmentation of reactive oxygen
species (ROS) production (Silic-Benussi et al., 2009, 2010c; Bia-
siotto et al., 2010). Further studies showed that even at lower
expression levels or through expression in the context of the viral
genome, p13 can increase ROS production and induce apoptosis
(D’Agostino et al., 2005; Hiraragi et al., 2005). There is evidence
that p13 can signiﬁcantly reduce the incidence and growth rate of
tumors arising from c-myc and ha-ras-co-transfected rat embryo
ﬁbroblasts (Silic-Benussi et al., 2004). It is not clear if p13 has
the same function when it is expressed at lower levels or in its
natural context. Interestingly, later studies found that p13 also
increased ROS production in normal primary T cells and activated
T cells, which was not associated with apoptosis (Silic-Benussi
et al., 2010b). The effect was speciﬁc because mutant p13 did
not have the same effect. Altogether it is suggested that p13
might help keep the infected cells “normal” through selectively
killing the transformed HTLV-1 cells. More studies are required
before we can understand how p13 functions in the persistence of
infection.
CONCLUSION
Human T-lymphotropic virus type-1 persistence depends on
establishment of latency. p12, p8, p30, and p13 play critical
functions to help the virus to establish latency, evade immune
FIGURE 2 |The contributions of p12, p8, p30 and p13 for the
establishment of persistent infection and cell transformation.
surveillance and promote transformation (Figure 2). After infec-
tion and before the establishment of an effective immune response
to HTLV-1, Tax and Rex can be expressed at high levels, produc-
ing as much virus as possible to infect and transform as many
cells as possible. At the same time that p13, p30, and HBZ inter-
fere with Tax-mediated transcription and reduce the total level of
viral expression, p30 retains tax/rex RNA and reduces Tax and Rex
directly. Once the host acquires immunity against HTLV-1, espe-
cially Tax, only the cellswith less Tax through cell regulation and/or
expression of p30, p13, and HBZ can survive. However, to main-
tain the infection and transform the cells, a low level of Tax expres-
sion is still required. The presence of p12 helps the infected cells
to avoid being recognized by CTL or NK cells, p30 can deregulate
innate immune responses, and p8 increases the efﬁciency of virus
transmission.
In addition, p12 and p30 can compensate for the low expres-
sion of Tax by promoting T cell proliferation and increasing
DNA instability, thereby transforming cells. The virus also evolves
ways to counteract some negative regulations, such as HBZ
decreasing p30 expression and Rex inhibiting p30 and rescu-
ing tax/rex export. These measures prevent the absolute latency
of the virus. In conclusion, the concerted expression of p12,
p8, p30, and p13 help the virus to establish and maintain an
incomplete latency in which the virus expresses low levels of
viral proteins. In turn, these maintain the infection and trans-
formation at the same time that they evade immune surveil-
lance.
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